Basel, March 20, 2014-Novartis has announced the launch of the Lucentis ® (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS ...

Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis. It is often used for age-related wet macular degeneration.

One of the many concerns about President Obama’s health care legislation is that it will encourage—if not eventually require—the government to approve the cheapest rather than the best ...

One of two Phase III studies of the drug Lucentis in patiets with diabetic macular edema met its goal, according to Genentech Inc. One of two Phase III studies of the drug Lucentis in patiets with ...

Full publication of results from the head-to-head study of Avastin (bevacizumab) and Lucentis (ranibizumab) in "wet" age-related macular degeneration (AMD) confirmed information previously leaked ...

The Lucentis-versus-Avastin debate just got a bit more complicated. Regeneron Pharmaceuticals ($REGN) won FDA approval for its macular degeneration drug Eylea ...

Avastin and Lucentis: two drugs with roughly the same molecular structure, both manufactured by the same drugmaker. One is approved to treat cancer, the other wet age-related macular degeneration.

The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...

The fine is only the latest act in a long-running drama over Lucentis, which is used to treat age-related macular degeneration, a common disease among older adults that can lead to blindness.

Lucentis (ranibizumab) is a brand-name eye injection that’s prescribed for certain eye conditions in adults. As with other drugs, Lucentis can cause side effects, such as eye pain or irritation ...

Patients were randomly assigned to receive Cimerli or Lucentis 0.5mg by intravitreal injection every 4 weeks. Results showed that treatment with Cimerli met the primary endpoint demonstrating a ...